Safety of long-acting β-agonists [2]

Annals of Internal Medicine

Volumn 145, Issue 9, 2006, Pages 706-707

  Lindberg, Mats Jacob ^a  

^a Institute for Rational Pharmacotherapy   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ANTIASTHMATIC AGENT;

BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; HUMAN; LETTER; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; RESPIRATORY CARE; SYSTEMATIC REVIEW; UNITED STATES; ASTHMA; METHODOLOGY; NOTE;

ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; META-ANALYSIS; RESEARCH DESIGN;

EID: 33750931806     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-145-9-200611070-00018     Document Type: Letter

References (4)

1. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904-12.
2. British guideline on the management of asthma. Thorax. 2003;58 Suppl 1:i1-94.
3. Global Initiative for Asthma Workshop Report: Global Strategy for Asthma Management and Prevention. NIH publication no. 02-3659. Bethesda, MD: National Institutes of Health; 2002 (updated 2004).
4. Currie GP, Lee DK, Srivastava P. Long-acting bronchodilator or leukotriene modifier as add-on therapy to inhaled corticosteroids in persistent asthma? Chest. 2005; 128:2954-62.